Tecentriq, Avastin combo trumps Nexavar in liver cancer
Hepatocellular carcinoma is a major cause of cancer deaths worldwide, affecting over 750,000 people every year.
Read More
Tag: Nexavar
BMS’ Opdivo disappoints in late-stage trial
However, a clear trend was demonstrated towards improvement in overall survival.
Read More
NICE bars NHS access to Lenvima, Nexavar for thyroid cancer
NHS treatment cost regulators have published draft guidelines rejecting funding for Eisai’s Lenvima and Bayer’s Nexavar for treating certain patients with thyroid cancer.
Read More
Eisai’s Lenvima hits liver cancer targets in PhIII trial
A late-stage trial assessing Eisai’s cancer drug Lenvima for hepatocellular carcinoma (HCC) has achieved its primary endpoint, pushing the drug closer to being filed for approval in this setting.
Read More
Bayer files for expanded use of Stivarga in liver cancer
Bayer has filed applications in Europe, the US and Japan seeking approval to expand the scope of its cancer drug regorafenib to include the second-line treatment of liver cancer.
Read More
NICE rejects Bayer’s Nexavar for liver cancer
Bayer’s Nexavar is the latest medicine currently available through the Cancer Drugs Fund that has failed to meet cost-effectiveness standards set by the National Institute for Health and Care Excellence.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
